NeuroFrontiers

ReachMD
NeuroFrontiers

Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health. So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.

  1. 4 THG 2

    Navigating Myasthenia Gravis in Adolescents and Young Adults

    Guest: Jonathan Strober, MD Misinterpreted symptoms and limited access to treatment can make it difficult to manage myasthenia gravis among adolescents and young adults. Join Dr. Jonathan Strober as he explains how we can address gaps in care for this population. Dr. Strober is a Professor of Neurology at the University of California, San Francisco and the Director of the Neuromuscular Clinic at UCSF Benihoff Children’s Hospital.

  2. 28 THG 1

    Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids

    Guest: Gil I. Wolfe MD, FAAN Rozanolixizumab is a fast-acting myasthenia gravis treatment that reduces IgG levels by blocking the neonatal Fc receptor. Dr. Gil Wolfe explains how it compares to other treatment options like corticosteroids, taking side effects and quality of life into consideration. Dr. Wolf is a SUNY Distinguished Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences.

  3. 20 THG 1

    FcRn Inhibitors: A Potential New Targeted Therapy Option

    Guest: Nicholas J. Silvestri, MD, FAAN FcRn inhibitors provide a targeted approach to generalized myasthenia gravis (gMG) treatment by reducing pathogenic antibodies. These therapies offer fewer side effects compared to traditional treatments like corticosteroids, improving both disease control and quality of life. Dr. Nick Silvestri, a Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences, explains this treatment’s potential.

  4. 20 THG 1

    The Evolving gMG Treatment Landscape

    Guest: Henry Kaminski, MD Generalized myasthenia gravis (gMG) is a complex autoimmune disease with a wide range of symptoms, from ocular issues to severe muscle weakness. As our understanding of the pathophysiology behind gMG evolves, so does our ability to improve patient management. Join Dr. Henry Kaminski as he examines emerging advancements in gMG treatment, including FcRN inhibitors and immune-targeting therapies. Dr. Kaminski is the Meta A. Neumann Professor of Neurology at the George Washington University School of Medicine and Health Sciences.

  5. 02/12/2024

    Beyond Plaques: Current Concepts in Alzheimer’s Pathophysiology

    Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD As our understanding of Alzheimer’s disease continues to evolve, it’s critical to understand the clinical and pathologic changes underpinning Alzheimer’s disease as it may be able to help guide early diagnosis and clinically meaningful management decisions.1 That’s why Drs. Douglas Scharre and Lori Guyton speak with Dr. Jennifer Caudle about Alzheimer’s disease pathophysiology and how it translates to clinical practice. Dr. Scharre is a Professor of Clinical Neurology and Psychiatry as well as the Director for the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Porsteinsson A, Isaacson R, Knox S, Sabbagh M, Rubino I. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386. © Eisai Inc. 2024. All Rights Reserved. AD-M2130 November 2024

  6. 02/12/2024

    The Time Is Now: Early Diagnosis and Intervention in Alzheimer’s Disease

    Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD Our understanding of the mechanisms underlying Alzheimer’s disease is growing, and these advances can help inform diagnosis and management strategies. In fact, as our understanding of Alzheimer’s disease evolves, our strategies to diagnose and manage the disease are changing to focus on early diagnosis and intervention.1 Joining Dr. Jennifer Caudle to discuss our current understanding of disease progression as well as the impact and benefit of diagnosing Alzheimer’s disease early are Drs. Douglas Scharre and Lori Guyton. Dr. Scharre is the Director of the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Atri A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med Clin North Am. 2019;103:263-293. © Eisai Inc. 2024. All Rights Reserved. AD-M2123 November 2024

  7. 22/10/2024

    Reducing the ALS Diagnostic Delay: The Impacts of a Rapid Access Clinic

    Guest: Kelly Gwathmey, MD ALS can take up to a year to diagnose, but researchers are hard at work trying to find ways to minimize diagnostic delays and errors. One such solution is the Rapid Access ALS Clinic, where patients were diagnosed an average of two months sooner. Here to talk about this work is Dr. Kelly Gwathmey, Professor of Neurology at the Virginia Commonwealth University School of Medicine who presented a session on this topic at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting.

  8. 18/10/2024

    Assessing TD’s Impact Using Clinician-Reported Measures: A Poster from Psych Congress Elevate

    Host: Ashley Baker, MSN, PMHNP Guest: Stacy Finkbeiner, PhD The IMPACT-TD Registry is an ongoing, real-world observational study that aims to better understand the multidimensional impacts of tardive dyskinesia (TD) on patients’ lives. To achieve this goal, the IMPACT-TD Scale was developed and used by clinicians involved with the study, and now the results from the interim analysis are available. Joining psychiatric nurse practitioner Ashley Baker to share the key findings on TD’s impact from the clinician perspective is Dr. Stacy Finkbeiner, U.S. Medical Director at Teva Pharmaceuticals.

Xem tất cả (144)

Giới Thiệu

Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health. So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.

Thông Tin

  • Nhà sáng tạo
    ReachMD
  • Năm hoạt động
    2015 - 2025
  • Tập
    144
  • Xếp hạng
    Sạch
  • Bản quyền
    © Copyright 2025 ReachMD. All rights reserved.
  • Trang web chương trình
    NeuroFrontiers

Có Thể Bạn Cũng Thích

Bạn cần đăng nhập để nghe các tập có chứa nội dung thô tục.

Luôn cập nhật thông tin về chương trình này

Đăng nhập hoặc đăng ký để theo dõi các chương trình, lưu các tập và nhận những thông tin cập nhật mới nhất.
Chọn quốc gia hoặc vùng

Châu Phi, Trung Đông và Ấn Độ

Châu Á Thái Bình Dương

Châu Âu

Châu Mỹ Latinh và Caribê

Hoa Kỳ và Canada